Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy

(2018) Luigino Calzetta et al.   CURRENT OPINION IN PHARMACOLOGY

Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients

(2018) Marco Contoli et al.   European Journal of Internal Medicine

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD

(2018) Maria Gabriella Matera et al.   Expert Opinion On Drug Safety

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

(2018) Alberto Papi et al.   LANCET

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

(2018) David A. Lipson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease

(2018) Meng-Ting Wang et al.   JAMA Internal Medicine

Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial

(2018) Jens M Hohlfeld et al.   Lancet Respiratory Medicine

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

(2017) Samy Suissa et al.   EUROPEAN RESPIRATORY JOURNAL

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary

(2017) Claus F. Vogelmeier et al.   EUROPEAN RESPIRATORY JOURNAL

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

(2017) Robert D Brook et al.   HEART

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

(2017) Jørgen Vestbo et al.   LANCET

Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies

(2017) Edward Kerwin et al.   LUNG

Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study

(2017) Dave Singh et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease

(2017) Anthony D'Urzo et al.   RESPIRATORY MEDICINE

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease

(2017) Roland Buhl et al.   RESPIRATORY MEDICINE

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease

(2017) Nicola A. Hanania et al.   RESPIRATORY MEDICINE

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

(2017) Paola Rogliani et al.   International Journal of Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison

(2016) Goran Medic et al.   ADVANCES IN THERAPY

A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD

(2016) Luigino Calzetta et al.   CHEST

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of aclidinium/formoterolversussalmeterol/fluticasone: a phase 3 COPD study

(2016) Claus Vogelmeier et al.   EUROPEAN RESPIRATORY JOURNAL

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial

(2016) Jørgen Vestbo et al.   LANCET

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

(2016) Dave Singh et al.   LANCET

Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3)

(2016) Donald A. Mahler et al.   RESPIRATORY MEDICINE

Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD

(2016) James F. Donohue et al.   RESPIRATORY MEDICINE

TIOtropium Safety and Performance In Respimat®(TIOSPIRTM): Analysis of Asian cohort of COPD patients

(2016) Nanshan Zhong et al.   RESPIROLOGY

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

(2016) Chris Kalberg et al.   Drugs in research & development

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

(2016) Claus Vogelmeier et al.   International Journal of Chronic Obstructive Pulmonary Disease

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age

(2016) Gary Ferguson et al.   International Journal of Chronic Obstructive Pulmonary Disease

Cardiac effects of current treatments of chronic obstructive pulmonary disease

(2016) Lies Lahousse et al.   Lancet Respiratory Medicine

Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling

(2015) Barbara Rinaldi et al.   BRITISH JOURNAL OF PHARMACOLOGY

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

(2015) Lorcan McGarvey et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives

(2015) Mario Cazzola et al.   DRUGS

Tiotropium and olodaterol fixed-dose combinationversusmono-components in COPD (GOLD 2–4)

(2015) Roland Buhl et al.   EUROPEAN RESPIRATORY JOURNAL

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS

(2015) M. Latorre et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies

(2015) Thomas M. Siler et al.   RESPIRATORY MEDICINE

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

(2015) Dave Singh et al.   RESPIRATORY MEDICINE

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

(2015) Dave Singh et al.   BMC Pulmonary Medicine

Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis

(2015) Andrea C Tricco et al.   BMJ Open

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial

(2015) Ronald Dahl et al.   BMJ Open

Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis

(2015) Kieran J Rothnie et al.   BMJ Open

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

(2015) Jinping P Zheng et al.   International Journal of Chronic Obstructive Pulmonary Disease

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial

(2015) Robert Wise et al.   npj Primary Care Respiratory Medicine

Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD

(2014) Bartolome Celli et al.   CHEST

Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use

(2014) Rajapriya Manickam et al.   Expert Opinion On Drug Safety

Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies

(2014) Qingxia Du et al.   PLoS One

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients

(2014) Jadwiga A. Wedzicha et al.   RESPIRATORY MEDICINE

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

(2014) Kai-Michael Beeh et al.   RESPIRATORY MEDICINE

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

(2014) Dave Singh et al.   BMC Pulmonary Medicine

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

(2014) Walter Vincken et al.   International Journal of Chronic Obstructive Pulmonary Disease

β2-Agonist Therapy in Lung Disease

(2013) Mario Cazzola et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

(2013) D. A. Mahler et al.   EUROPEAN RESPIRATORY JOURNAL

Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE study

(2013) Eric D. Bateman et al.   EUROPEAN RESPIRATORY JOURNAL

Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease

(2013) Mario Cazzola et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease

(2013) J.M. Hohlfeld et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Tiotropium Respimat Inhaler and the Risk of Death in COPD

(2013) Robert A. Wise et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD

(2013) J.F. Donohue et al.   RESPIRATORY MEDICINE

The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease

(2013) Marc Decramer et al.   International Journal of Chronic Obstructive Pulmonary Disease

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

(2013) Jadwiga A Wedzicha et al.   Lancet Respiratory Medicine

Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies

(2012) Ruth Tal-Singer et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Efficacy and safety of NVA237versusplacebo and tiotropium in patients with COPD: the GLOW2 study

(2012) Edward Kerwin et al.   EUROPEAN RESPIRATORY JOURNAL

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Rafael Lozano et al.   LANCET

28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: A randomized placebo-controlled trial

(2012) Gregory Feldman et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

(2012) Claus F Vogelmeier et al.   Lancet Respiratory Medicine

Long-term Safety and Efficacy of Indacaterol, a Long-Acting β 2 -Agonist, in Subjects With COPD

(2011) Kenneth R. Chapman et al.   CHEST

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

(2011) R. Buhl et al.   EUROPEAN RESPIRATORY JOURNAL

Safety of indacaterol in the treatment of patients with COPD

(2011) James Donohue et al.   International Journal of Chronic Obstructive Pulmonary Disease

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

(2010) C. Vogelmeier et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD

(2010) Mario Cazzola et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Prevalence of Comorbidities in Patients with Chronic Obstructive Pulmonary Disease

(2010) Mario Cazzola et al.   RESPIRATION

A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients

(2010) E.D. Bateman et al.   RESPIRATORY MEDICINE

Cardiovascular events in patients with COPD: TORCH Study results

(2010) P. M. A. Calverley et al.   THORAX

Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care

(2010) J. R. Feary et al.   THORAX

Efficacy of a new once-daily long-acting inhaled  2-agonist indacaterol versus twice-daily formoterol in COPD

(2010) R. Dahl et al.   THORAX

Vascular Dysfunction in Chronic Obstructive Pulmonary Disease

(2009) John D. Maclay et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Therapeutic Efficacy of a Combination of a  1-Adrenoreceptor (AR) Blocker and  2-AR Agonist in a Rat Model of Postmyocardial Infarction Dilated Heart Failure Exceeds That of a  1-AR Blocker plus Angiotensin-Converting Enzyme Inhibitor

(2009) I. Ahmet et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile

(2009) A. Gavalda et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD

(2008) D. M. Mannino et al.   EUROPEAN RESPIRATORY JOURNAL

Physical activity in patients with COPD

(2008) H. Watz et al.   EUROPEAN RESPIRATORY JOURNAL

Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease

(2008) Sonal Singh   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease

(2008) Donald P. Tashkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial

(2008) Donald P. Tashkin et al.   RESPIRATORY MEDICINE